评估复发/难治性多发性骨髓瘤患者的脆弱性：患者报告的脆弱性表型与国际骨髓瘤工作组脆弱性指数之间的比较

IF 3 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology Pub Date : 2025-06-04 DOI:10.1016/j.jgo.2025.102266

Daniela Krepper , Francesco Sparano , Johannes M. Giesinger , Gianluca Gaidano , Pasquale Niscola , Katia Codeluppi , Elisabetta Antonioli , Catello Califano , Lajos Floro , Ombretta Annibali , Claudio Fozza , Agostino Tafuri , Patrizio Mazza , Leonardo Potenza , Marco Vignetti , Michele Cavo , Maria Teresa Petrucci , Fabio Efficace

{"title":"评估复发/难治性多发性骨髓瘤患者的脆弱性：患者报告的脆弱性表型与国际骨髓瘤工作组脆弱性指数之间的比较","authors":"Daniela Krepper , Francesco Sparano , Johannes M. Giesinger , Gianluca Gaidano , Pasquale Niscola , Katia Codeluppi , Elisabetta Antonioli , Catello Califano , Lajos Floro , Ombretta Annibali , Claudio Fozza , Agostino Tafuri , Patrizio Mazza , Leonardo Potenza , Marco Vignetti , Michele Cavo , Maria Teresa Petrucci , Fabio Efficace","doi":"10.1016/j.jgo.2025.102266","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The International Myeloma Working Group Frailty Index (IMWG FI) is one of the most used frailty assessment tools in patients with multiple myeloma (MM). A patient-centered frailty tool based on patient-reported outcomes (PROs) has been recently proposed for patients with relapsed/refractory MM (RRMM): the Patient-Reported Frailty Phenotype (PRFP). This cross-sectional analysis aimed to replicate the PRFP within a real-world setting and to describe health-related quality of life (HRQoL) profiles based on this new patient-centered frailty classification.</div></div><div><h3>Materials and Methods</h3><div>This analysis was based on baseline data from a multi-center prospective observational study that included adult patients with RRMM. Frailty was assessed using the IMWG FI, and HRQoL was evaluated with the EORTC QLQ-C30 and its myeloma module (QLQ-MY20). For this analysis, the PRFP was also calculated, and Cohen's kappa was computed to examine the agreement between the two frailty assessment approaches. Descriptive statistics were used to investigate the HRQoL profiles of patients classified as frail, pre-frail, and fit.</div></div><div><h3>Results</h3><div>Five hundred eleven patients were enrolled. The median age was 69.8 years, and 44 % were female. According to IMWG FI and PRFP, 24.5 % and 25.1 % of patients were classified as frail, with a weighted Cohen's kappa of 0.27, indicating fair agreement. Frail patients, as classified by the PRFP, reported higher treatment side effects, disease symptoms, and worse future perspectives and body image compared to pre-frail and fit patients.</div></div><div><h3>Discussion</h3><div>Current findings suggest that the PRFP may be a valuable tool to assess frailty in patients with RRMM. However, further prospective studies are needed to better understand the value of PROs in a more accurate assessment of frailty in the RRMM setting.</div><div>Trial registration: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>: <span><span>NCT03190525</span><svg><path></path></svg></span></div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 6","pages":"Article 102266"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index\",\"authors\":\"Daniela Krepper , Francesco Sparano , Johannes M. Giesinger , Gianluca Gaidano , Pasquale Niscola , Katia Codeluppi , Elisabetta Antonioli , Catello Califano , Lajos Floro , Ombretta Annibali , Claudio Fozza , Agostino Tafuri , Patrizio Mazza , Leonardo Potenza , Marco Vignetti , Michele Cavo , Maria Teresa Petrucci , Fabio Efficace\",\"doi\":\"10.1016/j.jgo.2025.102266\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The International Myeloma Working Group Frailty Index (IMWG FI) is one of the most used frailty assessment tools in patients with multiple myeloma (MM). A patient-centered frailty tool based on patient-reported outcomes (PROs) has been recently proposed for patients with relapsed/refractory MM (RRMM): the Patient-Reported Frailty Phenotype (PRFP). This cross-sectional analysis aimed to replicate the PRFP within a real-world setting and to describe health-related quality of life (HRQoL) profiles based on this new patient-centered frailty classification.</div></div><div><h3>Materials and Methods</h3><div>This analysis was based on baseline data from a multi-center prospective observational study that included adult patients with RRMM. Frailty was assessed using the IMWG FI, and HRQoL was evaluated with the EORTC QLQ-C30 and its myeloma module (QLQ-MY20). For this analysis, the PRFP was also calculated, and Cohen's kappa was computed to examine the agreement between the two frailty assessment approaches. Descriptive statistics were used to investigate the HRQoL profiles of patients classified as frail, pre-frail, and fit.</div></div><div><h3>Results</h3><div>Five hundred eleven patients were enrolled. The median age was 69.8 years, and 44 % were female. According to IMWG FI and PRFP, 24.5 % and 25.1 % of patients were classified as frail, with a weighted Cohen's kappa of 0.27, indicating fair agreement. Frail patients, as classified by the PRFP, reported higher treatment side effects, disease symptoms, and worse future perspectives and body image compared to pre-frail and fit patients.</div></div><div><h3>Discussion</h3><div>Current findings suggest that the PRFP may be a valuable tool to assess frailty in patients with RRMM. However, further prospective studies are needed to better understand the value of PROs in a more accurate assessment of frailty in the RRMM setting.</div><div>Trial registration: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>: <span><span>NCT03190525</span><svg><path></path></svg></span></div></div>\",\"PeriodicalId\":15943,\"journal\":{\"name\":\"Journal of geriatric oncology\",\"volume\":\"16 6\",\"pages\":\"Article 102266\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of geriatric oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879406825000827\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of geriatric oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879406825000827","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

国际骨髓瘤工作组虚弱指数（IMWG FI）是多发性骨髓瘤（MM）患者最常用的虚弱评估工具之一。最近，针对复发/难治性MM （RRMM）患者提出了一种基于患者报告结果（PROs）的以患者为中心的脆弱性评估工具：患者报告的脆弱性表型（PRFP）。本横断面分析旨在在现实环境中复制PRFP，并描述基于这种新的以患者为中心的衰弱分类的健康相关生活质量（HRQoL）概况。材料和方法本分析基于一项包括成年RRMM患者的多中心前瞻性观察性研究的基线数据。使用IMWG FI评估脆性，使用EORTC QLQ-C30及其骨髓瘤模块（QLQ-MY20）评估HRQoL。对于这一分析，还计算了PRFP，并计算了Cohen的kappa，以检查两种脆弱性评估方法之间的一致性。描述性统计用于调查虚弱、体弱前期和健康患者的HRQoL概况。结果共纳入511例患者。中位年龄为69.8岁，44%为女性。根据IMWG FI和PRFP， 24.5%和25.1%的患者被分类为虚弱，加权科恩kappa为0.27，表明公平一致。根据PRFP分类的虚弱患者，与虚弱和健康前的患者相比，报告了更高的治疗副作用、疾病症状和更差的未来前景和身体形象。目前的研究结果表明，PRFP可能是评估RRMM患者脆弱性的一个有价值的工具。然而，需要进一步的前瞻性研究来更好地了解pro在RRMM环境中更准确评估脆弱性方面的价值。试验注册：ClinicalTrials.gov: NCT03190525

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index

Introduction

The International Myeloma Working Group Frailty Index (IMWG FI) is one of the most used frailty assessment tools in patients with multiple myeloma (MM). A patient-centered frailty tool based on patient-reported outcomes (PROs) has been recently proposed for patients with relapsed/refractory MM (RRMM): the Patient-Reported Frailty Phenotype (PRFP). This cross-sectional analysis aimed to replicate the PRFP within a real-world setting and to describe health-related quality of life (HRQoL) profiles based on this new patient-centered frailty classification.

Materials and Methods

This analysis was based on baseline data from a multi-center prospective observational study that included adult patients with RRMM. Frailty was assessed using the IMWG FI, and HRQoL was evaluated with the EORTC QLQ-C30 and its myeloma module (QLQ-MY20). For this analysis, the PRFP was also calculated, and Cohen's kappa was computed to examine the agreement between the two frailty assessment approaches. Descriptive statistics were used to investigate the HRQoL profiles of patients classified as frail, pre-frail, and fit.

Results

Five hundred eleven patients were enrolled. The median age was 69.8 years, and 44 % were female. According to IMWG FI and PRFP, 24.5 % and 25.1 % of patients were classified as frail, with a weighted Cohen's kappa of 0.27, indicating fair agreement. Frail patients, as classified by the PRFP, reported higher treatment side effects, disease symptoms, and worse future perspectives and body image compared to pre-frail and fit patients.

Discussion

Current findings suggest that the PRFP may be a valuable tool to assess frailty in patients with RRMM. However, further prospective studies are needed to better understand the value of PROs in a more accurate assessment of frailty in the RRMM setting.

Trial registration: ClinicalTrials.gov: NCT03190525

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of geriatric oncology ONCOLOGY-GERIATRICS & GERONTOLOGY

CiteScore

5.30

自引率

10.00%

发文量

379

审稿时长

80 days

期刊介绍： The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal welcomes the submission of manuscripts in the following categories: • Original research articles • Review articles • Clinical trials • Education and training articles • Short communications • Perspectives • Meeting reports • Letters to the Editor.